How Gilead Sciences Stock Gained 50%
Over nearly nine months, Gilead Sciences (GILD)’s stock jumped 51%, propelled not just by modest revenue gains but a striking 34% surge in net margins and an expanded P/E multiple. Behind the scenes, a mix of strong earnings beats, pivotal trial updates, and promising drug data rewrote the growth story—let’s dive in.
Below is an analytical breakdown of stock movement into key contributing metrics.
| 5092025 | 2032026 | Change | |
|---|---|---|---|
| Stock Price ($) | 94.9 | 143.3 | 50.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 28,734.0 | 29,086.0 | 1.2% |
| Net Income Margin (%) | 20.8% | 27.9% | 34.3% |
| P/E Multiple | 19.8 | 22.0 | 10.7% |
| Shares Outstanding (Mil) | 1,246.0 | 1,243.0 | 0.2% |
| Cumulative Contribution | 50.9% |
So what is happening here? The stock surged 51%, driven by a modest 1.2% rise in revenue, a strong 34% boost in net margin, and an 11% lift in the P/E multiple. Let’s explore the key events behind this growth.
Here Is Why Gilead Sciences Stock Moved
- Q2 2025 Earnings Beat: Gilead reported strong Q2 2025 results on August 7, 2025, with increased revenue and raised full-year guidance.
- HIV Trial Halt: On June 10, 2025, Gilead shares fell after the FDA halted two investigational HIV drug trials.
- Q3 2025 Earnings Strength: Gilead announced strong Q3 2025 results on October 30, 2025, with non-GAAP EPS beating expectations.
- Trodelvy Phase 3 Data: Positive Phase 3 results for Trodelvy in TNBC were published in NEJM on January 21, 2026, boosting stock.
- Q4 2025 Earnings Anticip: Anticipation for Q4 2025 earnings, due February 10, 2026, influenced stock toward period end.
Our Current Assesment Of GILD Stock
Opinion: We currently find GILD stock attractive. Why so? Have a look at the full story. Read Buy or Sell GILD Stock to see what drives our current opinion.
Risk: A good way to gauge risk with GILD is to check how far it’s fallen in past market downturns. It took a heavy hit, dropping nearly 60% during the Dot-Com Bubble. In the Global Financial Crisis and Covid sell-off, it slipped over 30%. Even the 2018 correction wasn’t kind, with a close to 30% dip. The inflation shock brought about a smaller but still meaningful 21% drop. So, while GILD has solid fundamentals, history shows it’s not immune when the market shakes.
GILD stock may have seen strong gains recently, but investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.